8-K: Reneo Pharmaceuticals and OnKure Announce Merger to Create Oncology-Focused Biopharma

Reneo Pharmaceuticals and OnKure, Inc. have agreed to merge, forming a Nasdaq-listed company focused on advancing OnKure's precision oncology pipeline, supported by a $65 million PIPE financing.

Summary

• Reneo Pharmaceuticals and OnKure, Inc. have announced a definitive merger agreement to combine the companies in an all-stock transaction.
• The combined company will focus on advancing OnKure's pipeline of precision medicines targeting oncogenic mutations in PI3K, with lead program OKI-219 in Phase 1 trials for solid tumors.
• The combined company is expected to operate under the name OnKure Therapeutics, Inc. and trade on the Nasdaq Global Market under the ticker symbol OKUR.
• Reneo has secured a $65 million PIPE financing to close concurrently with the merger, with participation from institutional investors.
• The combined company is expected to have approximately $120 million in cash at closing, providing funding through multiple clinical milestones and into the fourth quarter of 2026.
• Pre-merger OnKure stockholders are expected to own approximately 69.4% of the combined company, and pre-merger Reneo stockholders are expected to own approximately 30.6%, subject to adjustments based on Reneo's net cash at closing.
• The merger is subject to stockholder approval, SEC effectiveness of a registration statement, Reneo having at least $55 million in net cash at closing, and Nasdaq listing approval.

Sentiment

Score: 7

Explanation: The document presents a positive outlook for the combined company, highlighting the potential of OnKure's pipeline and the financial resources secured through the PIPE financing. However, it also acknowledges the risks and uncertainties associated with clinical development and regulatory approval.

Positives

• The merger creates a focused, clinical-stage biopharmaceutical company with a promising pipeline of precision oncology drugs.
• The combined company is expected to have a strong cash position of approximately $120 million, providing financial stability and runway.
• OnKure's lead program, OKI-219, has the potential to be a best-in-class, mutant-selective PI3K inhibitor with improved efficacy and safety.
• The merger brings together an experienced management team with a proven track record in drug development.
• The concurrent PIPE financing demonstrates strong investor confidence in the combined company's potential.

Negatives

• The merger is subject to several conditions, including stockholder approval and SEC effectiveness of a registration statement, which could delay or prevent the transaction from closing.
• The combined company will be dependent on the success of OnKure's early-stage clinical programs, which carry inherent risks and uncertainties.
• The combined company will need to raise additional capital in the future to continue advancing its pipeline, which may not be available on favorable terms or at all.

Risks

• The merger is subject to stockholder approval and other customary closing conditions, which may not be satisfied.
• The combined company's success is dependent on the clinical development and regulatory approval of OnKure's product candidates, which are subject to potential delays and uncertainties.
• The combined company will need to raise additional capital in the future, which may not be available on favorable terms or at all.
• The combined company may face challenges in integrating the operations and cultures of Reneo and OnKure.
• The combined company may face competition from other companies developing similar therapies.

Future Outlook

The combined company is expected to have sufficient funding to operate through multiple clinical milestones and into the fourth quarter of 2026. The company will focus on advancing OnKure's pipeline of precision medicines targeting oncogenic mutations in PI3K, with lead program OKI-219 in Phase 1 trials for solid tumors.

Management Comments

• Mike Grey, Executive Chairman and founder of Reneo Pharmaceuticals, stated that the transaction represents a compelling opportunity to deliver shareholder value as the OnKure team advances their PI3K inhibitors.
• Nicholas Saccomano, President and Chief Executive Officer of OnKure, stated that the merger will create a publicly traded company focused on advancing OnKures lead, mutant-specific programs targeting PI3K in breast cancer.

Industry Context

The merger reflects a trend in the biopharmaceutical industry towards consolidation and the pursuit of precision medicine approaches. The focus on PI3K inhibitors aligns with the growing interest in targeting oncogenic mutations in cancer.

Comparison to Industry Standards

• The document mentions that OKI-219 is a potential best-in-class, orally bioavailable, highly selective inhibitor of PI3KH1047R with approximately 80-fold selectivity for the mutated form of the enzyme compared to wild-type. This is compared to Alpelisib which has a 1-fold selectivity, STX-478 which has a 8.8-fold selectivity and RLY-2608 which has a 3.8-fold selectivity.
• The document also mentions that OKI-219 has shown superior activity and no weight loss or evidence of alteration of glucose homeostasis at doses >15x the Alpelisib activity is limited by toxicity preventing efficacious dosing to optimal efficacy.
• The document also mentions that OKI-219 is CNS penetrant in higher species, and shows strong activity in CNS models, equivalent to systemic activity.
• The document also mentions that OKI-219 shows low-dose activity in combination with SERDs and overcomes PI3K driven resistance in combination with tucatinib or trastuzumab.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders of Reneo and OnKure will be impacted by the merger, with their ownership percentages in the combined company subject to adjustments.
• Employees of both companies will be impacted by the merger, with potential changes in roles and responsibilities.
• Patients with cancer may benefit from the development of new therapies by the combined company.
• Investors in the PIPE financing will have an ownership stake in the combined company.

Next Steps

• Reneo and OnKure will seek stockholder approval for the merger.
• Reneo will file a registration statement on Form S-4 with the SEC.
• The companies will work to satisfy all closing conditions for the merger and concurrent PIPE financing.
• OnKure will continue to advance its clinical programs, including the PIKture-01 trial of OKI-219.

Key Dates

Keywords

merger, oncology, biopharmaceutical, precision medicine, PI3K, OKI-219, clinical trial, PIPE financing, Nasdaq, Reneo Pharmaceuticals, OnKure